Investors turn to biotech as vaccine roll-out cools sentiment on big pharma

Other sectors set to benefit as lockdown eases

Pedro Gonçalves
clock • 3 min read
Sectors such as telemedicine could boom over the course of the year
Image:

Sectors such as telemedicine could boom over the course of the year

Any halo earned from helping tackle the Covid-19 pandemic is likely to be short-lived for big pharma, according to asset managers who are turning their sights towards biotech and telehealth as the world slowly returns to normal.

On 8 December 2020, England became the first country to roll out a Covid-19 vaccine, a jab developed by Pfizer and BioNTech. In the months leading up to that, the healthcare sector took a leading role...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space

  • Get ahead of regulatory and technological changes affecting fund management

  • Important and breaking news stories selected by the editors delivered straight to your inbox each day

  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts

  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Markets

Thomas Coughlin of Kinesis Money

Fool me twice: The lessons we are yet to learn in the 100 years since Weimar hyperinflation

Need to recognise inherent flaws in current system

Thomas Coughlin
clock 22 October 2021 • 3 min read
The bank has pushed back against claims it may offload its asset management arm

State Street disavows claims of asset management sale - reports

Sparked by Invesco rumours

James Baxter-Derrington
clock 22 October 2021 • 1 min read
St James's Place CEO Andrew Croft

St James's Place AUM up 25% year-on-year

Improving consumer confidence fuelled net inflows

Jenny Turton
clock 21 October 2021 • 1 min read